Sundararaju Umashri, Rachoori Srinivas, Mohammad Abdulkader, Rajakumar Hamrish Kumar
Department of General Surgery, Government Medical College, Omandurar Government Estate, Chennai 600002, Tamil Nādu, India.
Department of Medicine, University of Novi Sad, Novi Sad 21000, Serbia.
World J Transplant. 2025 Jun 18;15(2):100460. doi: 10.5500/wjt.v15.i2.100460.
Heart transplantation (HTx) is a life-saving procedure for patients with end-stage heart failure and has undergone remarkable advancements since the first successful transplant in 1967. The introduction of cyclosporine in the 1970s significantly improved patient outcomes, leading to a global increase in transplants, including in India, where the practice has grown despite initial challenges. This review provides an extensive overview of HTx, focusing on current practices, technological advancements, and the ongoing challenges the field faces today. It explores the evolution of surgical techniques, such as minimally invasive and robotic-assisted procedures, and the management of posttransplant rejection through tailored immunosuppressive strategies, including new monoclonal antibodies and personalized therapies. The review also highlights emerging innovations such as mechanical circulatory support devices and xenotransplantation as potential solutions to donor shortages while acknowledging the ethical and logistical challenges these approaches entail. Furthermore, the analysis delves into the implications of using extended-criteria donors and the role of multidisciplinary teams in evaluating absolute and relative contraindications. Despite the progress made, the persistent issues of organ scarcity and ethical concerns underscore the need for ongoing research and innovation to further enhance the efficacy, safety, and accessibility of HTx.
心脏移植(HTx)是终末期心力衰竭患者的一种挽救生命的手术,自1967年首次成功移植以来取得了显著进展。20世纪70年代环孢素的引入显著改善了患者的预后,导致全球范围内移植手术数量增加,包括在印度,尽管最初面临挑战,但该手术仍有所发展。本综述对心脏移植进行了广泛概述,重点关注当前的实践、技术进步以及该领域目前面临的持续挑战。它探讨了手术技术的演变,如微创和机器人辅助手术,以及通过量身定制的免疫抑制策略管理移植后排斥反应,包括新型单克隆抗体和个性化疗法。该综述还强调了新兴的创新,如机械循环支持设备和异种移植,将其作为解决供体短缺的潜在方案,同时承认这些方法带来的伦理和后勤挑战。此外,分析深入探讨了使用边缘供体的影响以及多学科团队在评估绝对和相对禁忌证方面的作用。尽管取得了进展,但器官短缺和伦理问题的持续存在凸显了持续研究和创新的必要性,以进一步提高心脏移植的疗效、安全性和可及性。